Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abbott Laboratories (ABT) vs T-Rex 2X Inverse MSTR Daily Target ETF (MSTZ) Price & Performance

Abbott Laboratories
T-Rex 2X Inverse MSTR Daily Target ETF

Price performance

Price movement over the last 24 hours

Key statistics

Abbott Laboratories vs T-Rex 2X Inverse MSTR Daily Target ETF — how do they compare? Abbott Laboratories trades at $95.36 (market cap $166.94B), while T-Rex 2X Inverse MSTR Daily Target ETF trades at $12.55. The key difference: Abbott Laboratories pays a 2.63% dividend while T-Rex 2X Inverse MSTR Daily Target ETF pays none, and T-Rex 2X Inverse MSTR Daily Target ETF is trading nearer its 52-week high, Abbott Laboratories nearer its low. Which is the better fit depends on your goals.

ABTMSTZ
Market Cap
$166.94B
Sector
HealthLeveraged / Inverse
52-Week High
$136.62$27.92
52-Week Low
$82.57$3.12
Enterprise Value
$193.69B
Dividend Yield
2.63%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abbott Laboratories

Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.

The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.

T-Rex 2X Inverse MSTR Daily Target ETF

MSTZ trades at $11.08, down 0.27% on the day, with a bearish technical signal from moving averages and neutral oscillators. Key support lies at $10, resistance at $12. Financial ratios are unavailable, limiting fundamental assessment. Recent ETF-focused news mentions Strategy Inc. but provides no direct MSTZ updates, leaving a data gap for current company performance.

Outlook is cautious due to bearish technicals and lack of fundamental data. Investment opportunity hinges on forthcoming financial disclosures to clarify valuation and profitability. Primary risks include undefined business metrics and potential market volatility. Investors await earnings reports for clearer direction.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Abbott Laboratories

Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Read more on ABT

About T-Rex 2X Inverse MSTR Daily Target ETF

MSTZ is a leveraged ETF that seeks daily investment results corresponding to 200% of the inverse (opposite) of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bearish position on MSTR, a company known for its large Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from its stated daily objective.

Read more on MSTZ